DISRUPT CAD IV

By The Numbers

64
Patients
8
Japanese Sites
2
Year Follow-Up
30
Day MACE Rate = Primary Safety Endpoint
<50%
Residual Stenosis & No In-Hospital MACE = Primary Effectiveness Endpoint
64
Patient OCT Sub-Study

DISRUPT CAD IV Study Leadership

Japan CAD IV Headshot square
Shigeru SAITO, MD, FACC, FSCAI, FJCC
Interventional Cardiologist
Twin Recipient for G. O. Hartzler Master Operator Award (TCT 2019) and Ethica Award (EuroPCR 2016)
President of NPO International TRI Network & Director of ShonanKamakura General Hospital

 
                   

Learn More About DISRUPT CAD IV on ClinicalTrials.gov

Ready to Make Waves with Shockwave IVL?

ico email Connect
Disrupt

IT’S TIME TO

GET CRACKING

COUNTDOWN TO CAD III PRESENTATION

Days

Hours

Minutes

Seconds

TCT CONNECT

Caution: Investigational device. Limited by Federal (U.S.) law to investigational use.
ISI: https://shockwavemedical.com/important-safety-information-coronary/